Market Overview
Global Androgen Receptor Inhibitor market reached US$ YY million in 2025 and is expected to reach US$ YY million by 2033, growing at a CAGR of YY% during the forecast period 2026-2033.
An androgen receptor inhibitor used to treat metastatic carcinoma of the prostate. Androgen receptor inhibitor is also known as androgen antagonists or testosterone blockers. These are a class of drugs that prevent androgens like testosterone and dihydrotestosterone (DHT) from mediating their biological effects in the body. They act by blocking the androgen receptor (AR) and/or inhibiting or suppressing androgen production.
Androgen receptor inhibitors are used in the treatment of an assortment of androgen-dependent conditions in both males and females. They are used to treat men with prostate cancer, benign prostatic hyperplasia, and others and in women and girls, antiandrogens are used to treat acne, seborrhea, and hyperandrogenism among others
Market Scope
| Metrics | Details |
| CAGR | YY% |
| Market Size Available for Years | 2023-2033 |
| Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Type, Indication, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
The increasing burden of cancer
The rising burden of prostate cancer in individuals with androgenic alopecia, benign prostatic hyperplasia along other conditions is expected to drive the market growth.
Prostate cancer is estimated to develop in older men. About 6 in 10 prostate cancers are diagnosed in men who are 65 or older, and it is rare in men under 40. The average age of men when they are first diagnosed is about 67. It is estimated that about 299,010 new prostate cancer cases are expected to be diagnosed with prostate cancer. Thus, the above factors are expected to drive the market growth
Side effects associated with the inhibitors
Apart from the favorable outcomes, androgen receptor inhibitors have numerous side effects which are used in androgen-deprivation therapy. Side effects such as fatigue, anemia, bone mineral density loss and increase in the risk of breaking the bone, an increase in body mass, insulin resistance, and hypercholesterolemia. Thus, the above factors are expected to hinder the market growth.
Segment Analysis
The global medical drones market is segmented based on type, application, end-user and region.
The androgen synthesis inhibitors segment is expected to dominate the market growth
Androgen synthesis inhibitors (ASIs) are a class of drugs that reduce the body's production of androgens, primarily testosterone. Treatments for ailments including acne, prostate cancer, and excessive hair growth may benefit from this.
CRPC, in which the cancer cells proliferate even after castration or other therapies that reduce testosterone levels, is a common outcome for people with prostate cancer. In contrast to these conventional techniques, ASIs function by preventing the synthesis of androgens at distinct points along the synthesis route. For individuals with CRPC, this may offer further advantages in terms of tumor development management. Thus, the above factors are expected to hold the segment in the dominant position over the forecast period.
Geographical Analysis
North America is expected to hold a significant position in the androgen receptor inhibitor market share
North America holds a dominant position in the market share due to the high prevalence of prostate cancers and also the increased use of different kind of therapies that uses androgen receptor inhibitors. The increased research and developmental activities will also act as a factor for the growth of the market in the region.
The increase in research and developmental activities and the introduction of new drug options are also expected to drive the region's market growth.
Key Developments
March 2026: Bayer initiated Phase 2 trials for a next-generation androgen receptor inhibitor with enhanced mutant AR degradation capabilities, targeting castration-resistant prostate cancer patients.
January 2026: Janssen (Johnson & Johnson) received regulatory approval for expanded niraparib-enzalutamide combination as a precision AR pathway inhibitor in metastatic prostate cancer.
October 2025: Astellas Pharma submitted a supplemental NDA for darolutamide in non-metastatic CRPC with new combination data from global trials.
Competitive Landscape
The major global players in the market include Pfizer Inc., Astellas Pharma Inc., Sanofi SA, Johnson & Johnson Inc., Dr.Reddy's Laboratories, Novartis AG, MANUS AKTTEVA BIOPHARMA LLP, RPG Life Sciences Limited, Kekule Pharma and LEXICARE PHARMA PVT. LTD. among others.
Why Purchase the Report?
- To visualize the global androgen receptor inhibitor market segmentation based on type, indication, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of androgen receptor inhibitor market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global androgen receptor inhibitor market report would provide approximately 53 tables, 49 figures and 182 pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
